Cabozantinib and Nivolumab for Carcinoid Tumors
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Carcinoid Tumor
- Carcinoid Tumor of GI System
- Neuroendocrine Tumors
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
This is open-label, single-arm, phase II research study, studying the combination of cabozantinib and nivolumab in treating advanced carcinoid tumors. Carcinoid tumor is another term used to refer to neuroendocrine tumors that arise in organs such as the gastrointestinal tract, lungs, or thymus. The...
This is open-label, single-arm, phase II research study, studying the combination of cabozantinib and nivolumab in treating advanced carcinoid tumors. Carcinoid tumor is another term used to refer to neuroendocrine tumors that arise in organs such as the gastrointestinal tract, lungs, or thymus. The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits. Cabozantinib will be administered orally, once daily Nivolumab will be administered intravenously, every two weeks The target enrollment for this study is 35 participants. The U.S. Food and Drug Administration (FDA) has not approved cabozantinib or nivolumab for treating carcinoid tumors.
Tracking Information
- NCT #
- NCT04197310
- Collaborators
- Bristol-Myers Squibb
- Exelixis
- Investigators
- Principal Investigator: Kimberly Perez, MD Dana-Farber Cancer Institute
Get Well Soon